Multi-strain probiotics

Mechanism of action

Main mechanisms (strain- and context-dependent): (1) ecological competition with pathogens for nutrients and adhesion sites; (2) production of metabolites (lactic acid, acetate; in some cases indirect increases in butyrate through cross-feeding) with reduced pH and modulation of microbial communities; (3) strengthening of the intestinal barrier (mucins, tight junctions) and reduced permeability in selected models; (4) mucosal immune modulation (interaction with dendritic cells, Tregs, Th1/Th2/Th17 balancing; increased secretory IgA in some studies); (5) interference with pro-inflammatory signals (e.g. NF-κB) and reduction of endotoxins/microbial translocation in specific contexts; (6) effects on the gut-brain axis (metabolites, vagal signals) with possible implications for functional symptoms.

Supported benefits

• Reduced risk of antibiotic-associated diarrhea (AAD) in some populations and clinical contexts (strong)
• Prevention/reduction in the duration of acute infectious diarrhea (especially in pediatric age groups) with specific strains (moderate)
• Improvement in overall symptoms of irritable bowel syndrome (IBS) in some studies (pain, bloating), with high heterogeneity across formulations (moderate)
• Reduction in the incidence or duration of upper respiratory tract infections in some meta-analyses (small-to-moderate average effect, variable by strain) (moderate)
• Support in maintaining remission in pouchitis (some high-dose multi-strain formulations in specific contexts) (moderate)
• Reduction in inflammatory markers or intestinal permeability in subgroups (e.g., stress, obesity, NAFLD), with non-uniform results (limited)
• Improvement in atopic dermatitis/eczema or prevention during pregnancy/infancy: conflicting results and dependent on timing and strains (limited)

Safety & side effects

• Bloating, gas, abdominal cramps, changes in bowel habits (diarrhea or constipation), especially in the first 1–2 weeks
• Nausea or gastric discomfort in some individuals
• Rare cases of opportunistic infections (bacteremia/fungemia) in high-risk individuals, especially with central venous catheters or severe immunosuppression
• Rare: hypersensitivity reactions to formulation components (excipients, traces of milk/soy) rather than to the microorganism

FAQ

Is “multi-strain” always better than “single-strain”?

Not necessarily. Effectiveness depends on the clinical endpoint and the specific strains. A well-studied single-strain product may be more predictable than an unvalidated multi-strain one; a multi-strain formulation may offer complementary functions if the combination has been clinically tested.

Do probiotics stably colonize the intestine?

In most cases, colonization is transient: strains may be detectable during intake and for a period afterward, but they often decline after discontinuation. Effects may still occur through temporary metabolic activity and immunomodulation.

How many CFU are needed?

Studies use wide ranges (often 10^9–10^11 CFU/day). There is no universal threshold: what matters is the effective dose for that strain/formulation and the guarantee of CFU through the end of shelf life.

Can they help during antibiotic use?

In meta-analyses, some probiotics reduce the risk of antibiotic-associated diarrhea. The effect depends on strains, dose, population, and type of antibiotic; they do not replace therapies, and the choice should be contextualized.

Are they useful for the immune system?

Some studies show modest reductions in the incidence/duration of respiratory infections and changes in immune markers. Effects are variable and do not equate to indiscriminately “boosting” immunity.

What does “strain” mean, and why is it important?

Species and strain precisely identify the microorganism (e.g. Lactobacillus rhamnosus GG). Benefits and safety may vary among strains of the same species; this is why complete identification is essential for linking a product to the evidence.